Home›Compare›MyMenopauseRx vs Oak Longevity

MyMenopauseRx vs Oak Longevity: Which Is Better?

Head-to-head comparison of MyMenopauseRx and Oak Longevity based on our independent scoring across trust, value, experience, product range, and reputation — plus real pricing for the treatments they both offer.

Our Verdict

MyMenopauseRx scores higher overall in our independent evaluation (61.3/100 vs 60.3/100), leading on trust & safety, reputation. Oak Longevity comes out ahead on value, experience, product range. Oak Longevity has the lower entry price (from $79/mo vs $150/mo), so the better value depends on which treatment you need.

Gynecologist-founded virtual menopause practice that bills most commercial insurance or charges $150 per self-pay visit, prescribing FDA-approved HRT, non-hormonal therapy and branded GLP-1s to local pharmacies.

Visit MyMenopauseRx

Oak Longevity ('Oak Loves You') is a small cash-pay telehealth brand selling compounded GLP-1s, ED medication and NAD+/sermorelin. Headline prices require multi-month plans, and orders become non-refundable once sent to the pharmacy.

Visit Oak Longevity

Score Breakdown

DimensionMyMenopauseRxOak Longevity
Overall Score61.3/100 ✓60.3/100
Trust & Safety30%74/100 ✓55/100
Value25%58/10066/100 ✓
Experience20%58/10064/100 ✓
Product Range15%50/10062/100 ✓
Reputation10%55/100 ✓52/100

At a Glance

Founded20212024
HeadquartersChicago area, IL—
Publicly tradedNoNo
Treatment categories33
Treatments listed35
Starting price$150/mo$79/mo

Pricing Where They Compete

Prices shown are based on our most recent research and may not reflect current pricing. Telehealth providers update their pricing frequently. Always verify pricing directly with the provider before purchasing.

CategoryMyMenopauseRxOak Longevity
Weight Loss / GLP-1—$130–$235
Compounded Semaglutide

MyMenopauseRx

+Founder and clinicians are named, and most hold Menopause Society certification (MSCP); patients can keep the same clinician
+In-network with major commercial plans, so many insured patients pay only a copay; $150 flat self-pay rate otherwise
+Prescribes FDA-approved therapies to the patient's local pharmacy, and labs can be ordered on demand at discounted self-pay rates
−No cash-pay medication pricing; the cost of HRT or branded GLP-1s depends on the patient's pharmacy and insurance
−Doesn't accept Medicare, Medicaid or HMO plans, and testosterone is offered only in Illinois
−Very thin public reviews (Trustpilot 3.3/5 on 4), including complaints of rushed visits and repeated charges
Read the full MyMenopauseRx review →

Oak Longevity

+Compounded semaglutide from about $130/mo on multi-month plans, flat across doses
+Positive Trustpilot base (4.4/5, 54 reviews) citing fast approvals and responsive messaging
+Range spans GLP-1s, ED (tadalafil), NAD+ and sermorelin under one account
−Homepage 'from $89/mo' pricing is well below the ~$235/mo (semaglutide) and ~$285/mo (tirzepatide) one-month checkout prices
−Orders become non-refundable once sent to the pharmacy; mandatory arbitration and class-action waiver
−Opaque structure: three legal entity names, a Vancouver, BC BBB registration, and unnamed pharmacies and leadership
Read the full Oak Longevity review →

MyMenopauseRx vs Oak Longevity — FAQ

Is MyMenopauseRx better than Oak Longevity?

▾

MyMenopauseRx scores higher overall in our independent evaluation (61.3/100 vs 60.3/100), leading on trust & safety, reputation. Oak Longevity comes out ahead on value, experience, product range. Oak Longevity has the lower entry price (from $79/mo vs $150/mo), so the better value depends on which treatment you need.

Is MyMenopauseRx or Oak Longevity cheaper?

▾

Oak Longevity has the lower starting price (from $79/mo vs $150/mo for MyMenopauseRx). Starting prices are for the cheapest treatment each offers — compare the specific treatment you need, and check what each price includes.

What do MyMenopauseRx and Oak Longevity both offer?

▾

Both platforms treat Weight Loss / GLP-1. MyMenopauseRx covers 3 treatment categories total and Oak Longevity covers 3.

Still deciding?